The aberrant activation of NF-κB pathway may result from different causative mechanisms, like inactivating mutations or deletions of IκBα in Hodgkin’s lymphoma[23], activating mutations of NF-κB2 gene in B- and T-cell lymphomas[23], amplifications and/or translocations of NIK in multiple myeloma[2]. This evidence concerns the gene NFKB1 and T-cell non-Hodgkin lymphoma.